Connect your AI

Biote Corp. BTMD Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

NAG

Niagen Bioscience, Inc. Common StockNAGE

——

Other financials

Income statement

Revenue$44.9M-8.3%

Gross profit$31.0M-14.9%

Operating income$3.2M-67.3%

Net income$2.3M-83.4%

EPS (diluted)$0.06-83.8%

Balance sheet

Cash & equivalents$5.3M-87.2%

Total debt$103.4M-5.5%

Total equity-$56.1M+37.7%

Total assets$89.0M-27.8%

Cash flow

Operating cash flow$3.9M-39.7%

CapEx$362.0K-77.8%

Free cash flow$3.5M-26.8%

Valuation

Market cap$57.33M-51.2%

Enterprise value$155.43M-26.5%

P/E3.7×-0.1×

P/S0.3×-0.3×

Profitability

Gross margin70.1%-1.2pp

Operating margin15.4%-0.1pp

Net margin8.3%-2.3pp

FCF margin15.3%-3.2pp

Returns & leverage

Return on equity-21.4%—

Debt / equity9.1×—

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Biote Corp. in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: Biote Corp.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biote Corp.'s accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Biote Corp.'s accounts receivable, credit loss expense (reversal)?: Biote Corp. (BTMD) reported accounts receivable, credit loss expense (reversal) of -$433K in Q1 2026.
How has Biote Corp.'s accounts receivable, credit loss expense (reversal) changed year-over-year?: Biote Corp.'s accounts receivable, credit loss expense (reversal) decreased by 156.0% year-over-year, from $773K to -$433K.